Skip to main content
. 2014 Nov 1;37(11):1825–1832. doi: 10.5665/sleep.4180

Figure 5.

Figure 5

CRP in OSA patient serum activates THP-1 monocyte migration in vitro. (A) Recombinant CRP (2 μg/mL) added in RPMI medium with 20% FBS activates THP1 migration through Transwells under MCP1 gradient (5 nM in lower chamber). Anti-CD32a blocking antibody (10 μg/mL) but not control antibody significantly blocks this effect. One-Way ANOVA, * P < 0.05 compared to RPMI control, # P < 0.05 compared to CRP. (B) Serum from moderate and severe but not from mild OSA patient activates monocyte migration compared to serum from healthy controls. Anti-CD32a blocking antibody (10 μg/mL) added in OSA patients serum inhibits monocyte migration. Two-Way ANOVA, * P < 0.05 compared to control without antibody, $ P < 0.05 compared to mild OSA patient, # P < 0.005 compared to respective condition without antibody. (C) Recombinant CRP (2 μg/mL) added in serum of healthy controls induces an increase in monocyte migration. Mann-Whitney test, P = 0,002. (D) OSA, MS and combination of OSA+MS induce monocyte migration, expressed in percent of control. Two-Way ANOVA, * P < 0.05 compared to healthy controls, # P < 0.05 compared to OSA only group, $ P < 0.05 compared to MS only group. N = at least 4 independent experiments, error bars represent SEM.